In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
Russian pharmaceutical manufacturers have increased the number of clinical trials that are conducted in the domestic market as part of their efforts of import substitution, The Pharma Letter’s local correspondent reports. 31 October 2023
Biotechnology
French pharma major Sanofi is to buy $30 million of shares in MeiraGTx Holdings at a price of $7.50 per share. 30 October 2023
Biotechnology
The Coalition for Epidemic Preparedness Innovations (CEPI) is collaborating with US mRNA specialist Moderna, that will harness Moderna's platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health. 30 October 2023
Biotechnology
Indian drugmaker Intas Pharmaceuticals has inked an exclusive deal with Shanghai Henlius Biotech for the development and commercialization of serplulimab in Europe and India. 30 October 2023
Pharmaceutical
Swiss pharma giant Novartis has announced positive top-line results from the interim analysis of the ongoing pivotal Phase III ALIGN study of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgA nephropathy (IgAN). 30 October 2023
Biotechnology
The Food and Drug Administration (FDA) has approved Loqtorzi (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). 30 October 2023
Biotechnology
Danish dermatology company LEO Pharma has announced positive results from the Phase III DELTA 3 trial, an open-label extension study of its candidate delgocitinib. 30 October 2023
Pharmaceutical
Privately-held Italian drugmaker Chiesi today announced the appointment of Ralph Blom as the general manager for Chiesi Limited (covering the UK and Ireland), beginning January 2024. 30 October 2023
Biotechnology
In briefing notes released ahead of a key meeting on Tuesday, scientists at the US Food and Drug Administration describe uncertainty in the risks associated with a new gene editing technology. 30 October 2023
Pharmaceutical
The Global Health Innovative Technology (GHIT) Fund and United Nations-backed Medicines Patent have signed a Memorandum of Understanding (MOU) to strengthen their collaboration to improve access to medicines. 30 October 2023
Generics
The Slovenian generics drugmaker KRKA has achieved a rehearing of its case in the Russian Presidium of the Intellectual Rights Court (IPR), which could lead to the revocation of US pharma major AstraZeneca's patent for dapagliflozin - a drug for the treatment of type 2 diabetes, reports The Pharma Letter’s local correspondent. 30 October 2023
Biotechnology
German life sciences and pharma firm Merck KGaA today announced a strategic collaboration with China’s Jiangsu Hengrui Pharmaceuticals. 30 October 2023
Biotechnology
Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, saw its shares rise 5.5% to 235.80 Swedish kronor in early trading today, as it released financial results for the third quarter of 2023. 30 October 2023
Pharmaceutical
French drugmaker Ipsen has presented its sales performance for the year-to-date 2023. 30 October 2023
Biotechnology
UK-based investor Abingworth has raised $356 million for a new fund focused on clinical co-development in the life sciences. 30 October 2023
Biotechnology
M&A news last week saw Swiss pharma giant Roche announce last Monday it had agreed to acquire Roivant company Telavant and its TL1A-directed antibody RVT-3101 for $7.1 billion. Among research news, Johnson & Johnson presented much awaited new data at the European Society of Medical Oncology (ESMO) on its lung cancer drug Rybrevant. And Japan’s Eisai and US Biotech Biogen released new data for a subcutaneous formulation of their Alzheimer’s disease drug Leqembi at an AD clinical trials conference. Also of note, US pharma major Eli Lilly gained approval from the US Food and Drug Administration (FDA) for its ulcerative colitis drug Omvoh. 29 October 2023
Pharmaceutical
As it works to transition the COVID-19 oral antiviral treatments from government distribution to traditional health care distribution channels, US Health and Human Services (HHS) Secretary Xavier Becerra on Friday issued a request a request on the agency’s website for ongoing partnership during and after this transition. 28 October 2023
Biotechnology
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15 mL)/injection (100mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for moderately to severely active ulcerative colitis (UC) in adults. 27 October 2023
Pharmaceutical
In a third-quarter financial results season when most pharma companies have pleased shareholders with better-than-expected figures, the reaction to Sanofi’s presentation on Friday has provided a stark contrast. 27 October 2023
Pharmaceutical
There was good news for the makers of some diabetes and obesity drugs today, when the European regulator found no link to thyroid cancer scares. 27 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze